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Abstract
A disintegrin and metalloproteinase 10 (ADAM10) is a synaptic enzyme that has been previously shown to limit amyloid-β1–42
(Aβ1–42) peptide formation in Alzheimer’s disease (AD). Furthermore, ADAM10 participates to spine shaping through the
cleavage of adhesion molecules and its activity is under the control of synaptic plasticity events. In particular, long-term
depression (LTD) promotes ADAM10 synaptic localization triggering its forward trafficking to the synapse, while long-term
potentiation elicits ADAM10 internalization. Here, we show that a short-term in vitro exposure to Aβ1–42 oligomers, at a
concentration capable of inducing synaptic depression and spine loss, triggers an increase in ADAM10 synaptic localization
in hippocampal neuronal cultures. However, the Aβ1–42 oligomers-induced synaptic depression does not foster ADAM10
delivery to the synapse, as the physiological LTD, but impairs ADAM10 endocytosis. Moreover, Aβ1–42 oligomers-induced
inhibition of ADAM10 internalization requires neuronal activity and the activation of the NMDA receptors. These data suggest
that, at the synaptic level, Aβ1–42 oligomers trigger an aberrant plasticity mechanism according to which Aβ1–42 oligomers can
downregulate Aβ generation through the modulation of ADAM10 synaptic availability. Moreover, the increased activity of
ADAM10 towards its synaptic substrates could also affect the structural plasticity phenomena. Overall, these data shed new lights
on the strict and complex relationship existing between synaptic activity and the primary mechanisms of AD pathogenesis.
Keywords ADAM10 . Alzheimer disease . Amyloid-β . Synaptic plasticity
Abbreviations
AD Alzheimer’s disease




APP amyloid-β precursor protein
Ab antibody
BSA bovine serum albumin
CTRL non-treated cultures





NMDA receptors N-methyl-D-aspartate (NMDA) receptors
oAβ1–42 oligomers of Aβ1–42
PBS phosphate buffered saline
TEM transmission electron microscopy
TIF Triton-insoluble fraction
TTX tetrodotoxin
ElenaMarcello and StefanoMusardo contributed equally to this work and
are listed alphabetically
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s12035-019-1583-5) contains supplementary
material, which is available to authorized users.
* Elena Marcello
elena.marcello@unimi.it
* Monica Di Luca
monica.diluca@unimi.it
1 Department of Pharmacological and Biomolecular Sciences,
Università degli Studi di Milano, Via Balzaretti 9, 20133 Milan, Italy
2 Present address: Department of Basic Neuroscience, University of
Geneva, Rue Michel-Servet 1, 1206 Geneva, Switzerland
3 Department of Neurosciences, Psychology, Drug Research, and
Child Health, University of Florence, Florence, Italy
4 Department of Life Sciences, Università degli Studi di Milano,
Milan, Italy
5 Department of Biotechnology and Translational Medicine,




Disentangling the initial steps of Alzheimer’s disease (AD)
pathogenesis from full-blown pathology at a molecular and
cellular level remains a key step to fully understand disease
onset and progression. In this frame, it has been shown that
synapse dysfunction and spine loss represent an early event of
the disease rather than just a consequence of cell death [1].
Further, the synapses have been shown to be the main target of
the amyloid-β1–42 (Aβ1–42) peptide, whose deposition is one
of the main hallmarks of AD [2, 3].
The Aβ1–42 peptide derives from a transmembrane protein,
named amyloid-β precursor protein (APP), that is mainly lo-
calized in the pre-synaptic active zone and in the post-synaptic
compartment in the hippocampus and in the cortex [4].
The concerted action of theβ-secretase BACE-1 and the γ-
secretase towards APP generates Aβ1–42 [5]. Being APP
cleavage mutually exclusive, in neuronal cells, A disintegrin
and metalloproteinase 10 (ADAM10) cleaves APP within the
Aβ1–42 domain, thus generating the neuroprotective sAPPα
and precluding the formation of the Aβ1–42 peptide [6, 7].
The Aβ1–42 homeostasis is regulated by synapse activation:
increased activity enhances secretion of Aβ1–42, while reduced
activity inhibits it [8, 9]. Coherently, alsoADAM10 synaptic levels
and activity towards APP are under the control of activity-
dependent synaptic plasticity [10]. Long-term depression (LTD)
boosts ADAM10 membrane insertion by fostering its SAP97-
mediated forward trafficking to post-synaptic membrane, whereas
long-termpotentiation (LTP) reduces the enzymemembrane levels
by inducing AP2-dependent endocytosis [10].
On the other hand, Aβ1–42 can be considered a regulator of
neuronal activity [8] since once released, it affects in turn synaptic
transmission and plasticity. In particular, pathological Aβ1–42
levels giving rise to the formation of Aβ1–42 oligomers (oAβ1–
42) may indirectly cause a partial block of N-methyl-D-aspartate
(NMDA)-type glutamate receptors and shift the activation of
NMDA receptors-dependent signaling cascades towards pathways
involved in the induction of LTD and synaptic loss [11–13].
Here, we hypothesize that the oAβ1–42-induced plasticity path-
ways have a feedback effect on ADAM10 synaptic localization.
We show that short-term exposure to oAβ1–42 reduces ADAM10
endocytosis, thus leading to an increase in ADAM10 synaptic
localization. This effect is mediated by activation of synaptic
NMDA receptors containing the GluN2A subunit.
Results
Characterization of oAβ1–42 Effect on the Synapse
In order to set up a reliable in vitro system to analyze the effect
of oAβ1–42 on ADAM10 synaptic localization, we performed
a complete characterization of our experimental conditions.
First, oAβ1–42 preparation was monitored and controlled
by different means. As a negative control, we used a peptide
with the reverse sequence of Aβ (Aβ42–1). Coomassie stain-
ing and Western Blot analysis with an antibody detecting the
N-terminus of Aβ (6E10 antibody) indicated that our oAβ1–42
preparation resulted in a spectrum of oligomeric Aβ species,
from 4 up to 16 kDa (Fig. 1a). Transmission electron micros-
copy (TEM) analysis of oAβ1–42 confirmed the presence of
globular, oligomeric structures, while no fibrillar or
protofibrillar species were observed (Fig. 1b). Aβ42–1 prepa-
ration is mainly constituted of monomers and of aggregated
species. Western Blot analysis performed with 6E10 antibody
showed no signal in Aβ42–1 samples, as expected (Fig. 1a).
Consistent with previous studies [14, 15], we found that
oAβ1–42 species at a concentration of 500 nM applied to hip-
pocampal neurons for 24 hours (h) resulted in a significant
reduction in spine density as compared to non-treated cultures
(CTRL) or to cells exposed to Aβ42–1 (Fig. 1c). Moreover,
such concentration of oAβ1–42 did not increase the mortality
of the cells after 24 h of treatment, different from higher con-
centrations as 1 μM, 5 μM, and 10 μM (Fig. 1d).
oAβ1–42 species have been shown to facilitate synaptic
depression of neurons in acute slices [13, 16]. Accordingly,
hippocampal cultures exposed to oAβ1–42 for 30 min
displayed a global synaptic depression as indicated by elec-
trophysiological recordings of excitatory post-synaptic current
in miniature (mEPSCs) (Fig. 1e) as well as upon the delivery
of the classical LTD protocol (20 μM NMDA and 20 μM
glycine for 3 min, chemical LTD; Fig. 1e; [17, 18]).
Moreover, we used a biochemical approach and we purified
the Triton-insoluble fraction (TIF) that is enriched in post-
synaptic proteins. As shown in Fig. 1f, the treatment with
oAβ1–42 (500 nM, 30 min) induced a significant dephosphor-
ylation of serine 845 of the GluA1 subunit of α-amino-3-hy-
droxy-5-methyl-4-isoxazolepropionic acid (AMPA) recep-
tors, without any significant change in GluA1 synaptic levels,
confirming that this concentration elicits synaptic depression
[19]. No changes in the total and synaptic levels of NMDA
receptor subunits and in PSD-95 were observed (Fig. 1f;
Suppl. Fig. 1A, B).
These results suggest that our oAβ1–42 preparation triggers
a synaptic depression affecting specifically AMPA mediated
conductance.
oAβ1–42 Promote ADAM10 Synaptic Localization
Impairing Its Endocytosis
Given that ADAM10 synaptic localization is regulated by
synaptic plasticity [10], can oAβ1–42 modify ADAM10 syn-
aptic levels? To address this issue, we exposed hippocampal
neuronal cultures to oAβ1–42 (500 nM, 30 min). As shown in
Fig. 2a, bath application of oAβ1–42 significantly increases the
co-localization of ADAM10 with a post-synaptic marker, as
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PSD-95, along dendrites when compared to untreated or
Aβ42–1-treated cells.
To further confirm these results by a biochemical approach, we
purified the TIF. ADAM10 levels were significantly increased in
the TIF upon oAβ1–42 treatment (Fig. 2b), indicating that oAβ1–42
promote ADAM10 synaptic localization. We have previously
shown that LTD induction fosters the SAP97-mediated
ADAM10 trafficking to the synapse [10]. However, no alterations
of SAP97 synaptic localization were detected upon oAβ1–42 treat-
ment (Fig. 2b; Suppl. Fig. 2A). In addition, nomodifications of the
Fig. 1 Aβ oligomers characterization and effects on the synapses. a A
representative Coomassie-stained polyacrylamide gel and Western blot
analysis of Aβ42–1 and oAβ1–42. The image shows the presence of olig-
omers formation for Aβ1–42 and monomer and aggregated forms for
Aβ42–1. b TEM revealed globular but not fibrillar structures for oAβ1–
42 preparation, scale bar 500 nm. c Representative confocal images of
GFP-transfected primary hippocampal neurons. The analysis shows that
oAβ1–42 (500 nM, 24 h) reduces spine density (CTRL 4.58 ± 0.18; Aβ42–
1 4.15 ± 0.12; oAβ1–42 3.36 ± 0.18; **p < 0.01, ***p < 0.001; one-way
ANOVA, n = 34–45). Scale bar 5 μm. d MTT test shows that exposure
to oAβ1–42 for 24 h induces cell death starting from a concentration of
1 μM (**p < 0.01, ***p < 0.001 one-way ANOVA, oAβ1–42 vs CTRL,
n = 4). e Representative traces of mEPSCs collected in hippocampal neu-
rons before and after oAβ1–42 exposure (upper panel) and before and after
chemical LTD (cLTD, lower panel). At least 21 neurons before and after
each treatment (oAβ1–42 or cLTD) have been analyzed and the related
analysis of mEPSC amplitudes, here shown as cumulative probability,
includes these n of excitatory events: 1550 (before oAβ1–42, black line)
vs 970 (after oAβ1–42, red line), CTRL vs oAβ1–42 p = 0.0075; 2100
(before cLTD, black line) vs 1970 (after cLTD, green line), CTRL vs
cLTD p < 0.0001. f Western blot analysis of synaptic protein levels in
total homogenate (HOMO) and synaptic fraction (TIF) upon oAβ1–42
treatment (500 nM, 30 min). The quantification shows that oAβ1–42 in-
cubation for 30 min induces a decrease of GluA1 phosphorylation at 845-
residue (GluA1p845/GluA1, HOMO: CTRL 100 ± 20.76%, Aβ42–1
104.80 ± 13.77%, oAβ1–42 55.22 ± 9.05%; TIF: CTRL 100 ± 14.13%,
Aβ42–1 92.40 ± 6.21%, oAβ1–42 67.36 ± 9.30%, *p < 0.05, **p < 0.001,
one-way ANOVA, n = 7–11). oAβ1–42 exposure does not induce signif-
icant changes of GluA1, NMDA receptors subunits (GluN1, GluN2A,
GluN2B), and PSD-95 expression and synaptic localization
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synaptic levels of β2-adaptin, one of the subunits of the AP2
complex responsible for ADAM10 endocytosis [10], were ob-
served (Fig. 2b; Suppl. Fig. 2B).
To determine the cellular mechanism underlying oAβ1–42-in-
duced increase inADAM10 synaptic localization,we analyzed the
association of ADAM10 to SAP97 and AP2 complex. As shown
in Fig. 2c, the oAβ1–42 treatment does not alter the interactionwith
SAP97, while significantly decreases the interaction with β2-
adaptin, one of the subunits of AP2 complex. These results dem-
onstrate that acute exposure to oAβ1–42 affects ADAM10 synaptic
localization because of a decrease of endocytosis rather than to an
increase of forward trafficking.
oAβ1–42-Triggered ADAM10 Increased Synaptic
Localization Is Mediated by the Activation of Synaptic
GluN2A-Containing NMDARs
To identify which of the cellular pathways triggered by oAβ1–42 is
responsible for the increase in ADAM10 synaptic localization, we
analyzed the effect of the blockade of different events. First, we
took advantage of the action potential blocker tetrodotoxin (TTX)
(500 nM), and we observed that TTX pre-incubation prevents the
oAβ1–42-induced increase of ADAM10 in the TIF (Fig. 3a), indi-
cating the involvement of neuronal synaptic activity.
In the adult forebrain, synaptic NMDA receptors are predom-
inantly di-heteromeric GluN1/GluN2A and tri-heteromeric
GluN1/GluN2A/GluN2B receptors [20, 21]. In light of this obser-
vation and considering the key role of GluN2A-containing
NMDA receptors in plasticity phenomena [22, 23], we examined
the effect of NVP-AAM077, a GluN2A-preferring antagonist
[24]. The analysis of ADAM10 levels in the TIF shows that the
presence of NVP-AAM077 fully prevents the increased localiza-
tion of ADAM10 in the synapses induced by oAβ1–42 (Fig. 3b).
Notably, the presence of ifenprodil, an antagonist of GluN2B-
containing NMDA receptors, does not affect the oAβ1–42-trig-
gered increase in ADAM10 synaptic levels, thus indicating the
specific involvement of GluN2A-containing NMDA receptors
(Suppl. Fig. 3).
Discussion
In this study, we provide evidence for aberrant plasticity phe-
nomena by which oAβ1–42 control synaptic function and the
Fig. 2 oAβ1–42 treatment increases ADAM10 synaptic localization,
impairing its endocytosis. a Confocal images of primary hippocampal
neurons stained with PSD-95 (red) and ADAM10 (green). Cells were
untreated (CTRL) or incubated for 30 min with either oAβ1–42 or
Aβ42–1 (500 nM). The challenge with oAβ1–42 increases the ADAM10/
PSD-95 co-localization index (CTRL 100 ± 2.48%, Aβ42–1 95.59 ±
2.69%, oAβ1–42 123.1 ± 5.86%; *p < 0.05, **p < 0.01 Kruskall-Wallis
one-way analysis on variance, n = 30). Representative images of
ADAM10/PSD-95 co-localization (white) are shown on the right, scale
bar 5 μm. b Representative images of western blot analysis of ADAM10
in the TIF of primary hippocampal neurons. The quantitative analysis
shows that oAβ1–42 increase ADAM10 synaptic localization (CTRL
100 ± 16.55%, Aβ42–1 102.7 ± 18.9%, oAβ1–42 222 ± 32.46%;
*p < 0.05 one-way ANOVA, n = 3). c Representative images of co-
immunoprecipitation between ADAM10 and either SAP97 or β2-
adaptin. The quantitative analysis shows that oAβ1–42 treatment reduces
the interaction with β2-adaptin without affecting the interaction with
SAP97 (SAP97 96.95 ± 5.26%, β2-adaptin 57.39 ± 17.81%, *p < 0.05 t
test oAβ1–42 vs Aβ42–1, n = 3)
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generation of Aβ1–42 itself. Primary hippocampal cultures
were treated with a preparation of oAβ1–42 able to induce
synaptic depression in 30 min and spine loss in 24 h, in the
absence of cell death. In these experimental conditions, oAβ1–
42 short-term exposure results in an increase in ADAM10
synaptic availability. Although it has been shown that LTD
fosters SAP97-mediated ADAM10 delivery to the post-
synaptic compartment [10], oAβ1–42 treatment leads to a de-
crease in the association between ADAM10 and AP2 com-
plex, which is responsible for the endocytosis of the enzyme,
without affecting the binding to SAP97 (Fig. 3c). Therefore,
the increase in ADAM10 synaptic localization is due to the
impairment of its endocytosis rather than to a stimulation of its
forward trafficking, suggesting that the molecular pathways
underlying physiological LTD and regulating ADAM10 are
profoundly different from those responsible for oAβ1–42-in-
duced depression.
Considering that several studies demonstrated that oAβ1–42
inhibit the maintenance of hippocampal LTP [8, 25, 26] and
that ADAM10 endocytosis is regulated by LTP, we can also
hypothesize that the oAβ1–42-induced impairment in
ADAM10 endocytosis is in line with a disorder in mechanism
of LTP. Thus, overall our data indicate that oAβ1–42 triggers
aberrant plasticity phenomena.
We provide also a mechanistic inside for this aberrant plasticity
of oAβ1–42 action. oAβ1–42 engage a pathway that requires neu-
ronal activity and the activation of the GluN2A-containing
NMDA receptors. Even if several studies reported the role of the
extra-synaptic GluN2B-containing NMDA receptors [27–29], our
data highlight that acute exposure to oAβ1–42 triggers a synaptic
event that involvesGluN2A-containingNMDA receptors. Indeed,
the presence of an inhibitor of GluN2B-containing NMDA recep-
tors does not prevent the oAβ1–42-induced increase in ADAM10
synaptic localization.
Taken together, these data suggest that a short-term exposure to
oAβ1–42 engages a negative feedback mechanism according to
which oAβ1–42 can downregulate Aβ generation through themod-
ulation of ADAM10 synaptic availability. Moreover, the increased
activity of ADAM10 towards its synaptic substrates could tune
synaptic transmission and structural plasticity. It has been shown
that the sAPPα, which is released afterADAM10 cleavage ofAPP,
is able to acutely modulate synaptic strength when applied in vitro
[30]. Furthermore, ADAM10-mediated shedding of N-cadherin
controls spine shaping and AMPA receptors function [31].
Overall, here, we show that oAβ1–42 can trigger aberrant
plasticity pathways and, thereby, affect synaptic plasticity.
Since the synapses are considered to be an early site of pathol-
ogy in AD [32] and loss of synapses is the best pathologic
correlate of cognitive impairment in AD patients [33], under-
standing the molecular underpinnings leading to synaptic dys-
function will aid in the development of tailored synapse-
targeted therapies for AD.
Methods
Amyloid Oligomers Preparation
Aβ1–42 and Aβ42–1 peptides were purchased from Bachem
(Bubendorf, Switzerland) and oligomers were prepared
Fig. 3 oAβ1–42-triggered ADAM10 increase in synaptic localization
requires neuronal activity and the activation of GluN2A-containing
NMDA receptors. a Representative images of Western Blot analysis of
ADAM10 levels in the TIF of primary hippocampal neurons treated with
TTX for 15 min and then challenged with Aβ42–1 or oAβ1–42. The quan-
titative analysis shows that TTX prevents the oAβ1–42-induced increase
in ADAM10 synaptic localization (Aβ42–1 100 ± 5.80%, oAβ1–42
187.80 ± 29.51%, oAβ1–42 + TTX 79.57 ± 5.84%, *p < 0.05, one-way
ANOVA, n = 3). b The presence of NVP-AAM077 (NVP, 50 nM), an
inhibitor of GluN2A-containing NMDA receptors, prevents oAβ1–42-
triggered augment in ADAM10 synaptic levels (Aβ42–1 100 ± 1.52%,
oAβ1–42 130 ± 8.91%, Aβ42–1 + NVP 92.86 ± 3.19%, oAβ1–42 + NVP
90.37 ± 4.41, *p < 0.05, **p < 0.001 one-way ANOVA, n = 3). c
Scheme of the mechanism according to which oAβ1–42 affect
ADAM10 synaptic localization
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according to [34]. The lyophilized peptides were dissolved in
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigma, St. Louis,
MO, USA) and aliquoted before removing HFIP. oAβ1–42
were obtained by incubating at 4 °C for 24 h in Neurobasal
mediumwithout Phenol red. The quality of the oligomer prep-
aration was controlled separating the protein onto a 13% Tris-
Tricine gels and performing Coomassie staining and western
blots against the amyloid-β peptide (6E10; Covance, CA,
USA). To analyze the presence of oligomeric and fibrillar
forms, TEM experiments were performed by applying 5 μl
of protein suspension to a glow-discharge coated carbon grid
(Cu 300 mesh, Electron Microscopy Sciences, PA, USA) for
1 min and then negatively stained with 2% Uranyl acetate.
Sample was observed at an EFTEM Leo912ab (Zeiss,
Germany) operating at 100 kV and digital images were ac-
quired by a CCD camera 1kx1k (Proscan, Germany) and
iTEM software (Olympus, Germany).
Neuronal Cultures Preparation, Transfection,
and Treatments
Primary hippocampal neurons cultures were prepared from
embryonic day 18–19 rat hippocampi as previously described
[35]. The Institutional Animal Care and Use Committee of
University of Milan and the Italian Ministry of Health
(#326/2015) approved all the experiments involving primary
neuronal cultures preparation.
Neurons were transfected with eGFP plasmid using the
calcium phosphate precipitation method at 10 days in vitro
(DIV) for spines density analysis. All the treatments were per-
formed atDIV14 using the following reagents concentrations:
either oAβ1–42 or Aβ42–1 500 nM (30 min), NVP-AAM077
(GluN2A-containing NMDA receptor antagonist, TOCRIS,
Bristol, UK) 50 nM (pre-incubation of 15 min), TTX
(Tetrodotoxin, TOCRIS) 500 nM (pre-incubation of 15 min),
and ifenprodil (GluN2B-containing NMDA receptor
antagonist, TOCRIS) 3 μM (pre-incubation of 5 min).
Neuronal cultures were treated with either oAβ1–42 or Aβ42–
1 at different concentrations (500 nM, 1 μM, 5 μM, and
10 μM) and, after 24 h, the MTT test was performed accord-
ing to [36] to evaluate the cells viability.
Synaptic Fraction Purification, Western Blot,
and Co-immunoprecipitation Analysis
After treatment, samples were processed for the purification of
the Triton-insoluble fraction (TIF), a fraction enriched in post-
synaptic density proteins [35]. After quantification, total ho-
mogenate and TIF proteins were resolved with SDS-PAGE
method; co-immunoprecipitation experiments were per-
formed as described in [10, 35].
Antibodies
The following antibodies (Ab) were used: ADAM10 pur-
chased from Abcam ab39153 (Cambridge, UK), SAP97 from
Stressgen ADI-VAM-PS005-D (San Diego, CA, USA), β2-
Adaptin from BD Bioscience 610382 (NJ, USA), Tubulin
T9026 and GluN2A M264 from Sigma-Aldrich, GluA1 75-
327, PSD-95 75-028, GluN2B 75-097, and GFP 75-132 from
Neuromab (Davis, CA, USA), GluA1-p845 04-1073 and
6E10 SIG39320-200 (Covance) from Millipore (Billenca,
MA, USA), and GluN1 320500 from Thermo Fisher
(Waltham, MA, USA). Peroxidase-conjugated secondary
Abs were purchased from Bio-Rad (Hercules, CA, USA).
AlexaFluor secondary Abs were purchased from Thermo
Fisher.
Immunocytochemistry and Confocal Microscope
Acquisition
For ADAM10/PSD-95 co-localization and spine morphology
studies, treated hippocampal neurons were fixed 7 min in 4%
paraformaldehyde plus 4% sucrose in phosphate buffered sa-
line (PBS) at room temperature. Then, cells were extensively
washed with PBS supplemented with CaCl2 and MgCl2,
permeabilized with 0.2% Triton-X100 and incubated for 2 h
at room temperature with 5% BSA in PBS. Primary and sec-
ondary antibodies were applied in 5% bovine serum albumin
(BSA) in PBS. Cells were labeled with primary antibodies
overnight at 4 °C. Cells were washed and then incubated with
secondary antibodies for 1 h at room temperature. Cells were
then washed in PBS and mounted on glass slides with
Fluoromount mounting medium (Sigma-Aldrich).
Fluorescence images were acquired by using Zeiss Confocal
LSM510 system (Zeiss, Jena, Germany) with a sequential
acquisition setting at 1024 × 1024 pixels resolution; for each
image, two up to four 0.5-μm sections were acquired and a z
projection was obtained [31].
Cell Culture Electrophysiology
Whole-cell patch-clamp recordings of mEPSCs were obtained
from DIV 15–16 neurons using a Multiclamp700A amplifier
(Molecular Devices) and pClamp-10 software (Axon
Instruments, Foster City, CA). Recordings were performed
in the voltage-clamp mode. Currents were sampled at 5 kHz
and filtered at 2–5 kHz. Recording pipettes, tip resistances of
3–5 MΩ were filled with the intracellular solution of the fol-
lowing composition (in mM): 130 potassium gluconate, 10
KCl, 1 EGTA, 10 Hepes, 2 MgCl2, 4 MgATP, 0.3 Tris-GTP.
At the beginning of the experiment, mEPSCs have been re-
corded in the external solution [Krebs’ Ringer’s-HEPES
(KRH)] with the following composition (in mM): 125 NaCl,
5 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2 CaCl2, 6 glucose, 25
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HEPES-NaOH, pH 7.4 in which also TTX (0.5 μM),
bicuculline (20 μM, Tocris, Bristol, UK), and strychnine
(1 μM, Sigma-Aldrich, Milan, Italy) were included. Then, to
induce chemical LTD, we applied NMDA (20 μM) and gly-
cine (20 μM, Sigma-Aldrich, Milan, Italy) for 3 min at room
temperature in Mg2+-free KRH containing TTX (0.5 μM),
bicuculline (20 μM), and strychnine (1 μM). Thirty minutes
after this treatment, mEPSCs have been collected again in the
starting KRH solution. Synaptic depression has been also in-
duced in cultures by 30 min of oAβ1–42 (500 nM) in Mg
2+-
free KRH containing only TTX (0.5 μM), bicuculline
(20 μM) and strychnine; at the end of this treatment,
mEPSCs have been recorded in normal KRH and analyzed.
Off-line analysis of miniature events was performed by the
use of Clampfit- pClamp-10 software.
Data Quantification and Statistical Analysis
Quantification of Western Blot analysis was performed by
means of computer-assisted imaging (Image Lab, Biorad).
The levels of the proteins were expressed as relative optical
density (OD) measurements and normalized on tubulin.
Values are expressed as mean ± S.E.M. of at least three inde-
pendent experiments.
Co-localization analysis was performed using Zeiss AIM
4.2 software and spines analysis was performed with ImageJ
software (National Institute of Health, Bethesda, MD, USA).
For co-localization, and morphological analysis, cells were
chosen randomly for quantification from 4 different coverslips
(2–3 independent experiments), images were acquired using
the same settings/exposure times, and at least 10 cells for each
condition were analyzed. Statistical evaluations were per-
formed by using 2-tailed Student’s t test (a p value less than
0.05 was considered significant) or, when appropriate, by
using one-way ANOVA followed by Bonferroni’s post hoc
test or Kruskal-Wallis analysis of variance followed by
Dunn’s post hoc test.
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